ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
ANIP sits 47% above its 52-week low of $54.1.
Summary
ANI Pharmaceuticals announced record financial results for the fourth quarter and full year 2025, alongside reaffirming its strong 2026 financial guidance. The company reported significant growth, particularly in its Rare Disease segment, with Cortrophin Gel net revenues increasing 87.6% in Q4 2025. This official press release confirms the positive performance and outlook, which was simultaneously reported by other news wires highlighting a significant beat on Q4 adjusted EPS and robust 2026 revenue and EPS guidance. The record performance and reaffirmed positive outlook indicate strong operational execution and continued growth momentum, reinforcing investor confidence in the company's strategic direction and financial health. Investors will now focus on the company's execution of its 2026 priorities, especially the expansion of its Rare Disease organization and the continued performance of key products like Cortrophin Gel.
At the time of this announcement, ANIP was trading at $79.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $54.10 to $99.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.